Key result
Novel N-phenylbenzamide and N-phenylacetophenone compounds exhibit potent in vitro antiviral activity against HCV and EV71.
Novel N-phenylbenzamide and N-phenylacetophenone compounds demonstrate potent in vitro antiviral activity against HCV and EV71, warranting further in vivo investigation.
Answers are grounded in this paper and cite their sources.
These benzamide hits require in vivo validation before any clinical consideration; leaves open their viability as future antivirals.
A series of novel N-phenylbenzamide and N-phenylacetophenone compounds were synthesized and evaluated for their antiviral activity against HCV and EV71 (strain SZ-98). The biological results showed that three compounds (23, 25 and 41) exhibited considerable anti-HCV activity (IC50=0.57-7.12 μmol/L) and several compounds (23, 28, 29, 30, 31 and 42) displayed potent activity against EV71 with the IC50 values lower than 5.00 μmol/L. The potency of compound 23 (IC50=0.57 μmol/L) was superior to that of reported compounds IMB-1f (IC50=1.90 μmol/L) and IMB-1g (IC50=1.00 μmol/L) as anti-HCV agents, and compound 29 possessed the highest anti-EV71 activity, comparable to the comparator drug pirodavir. The efficacy in vivo and antiviral mechanism of these compounds warrant further investigations.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2015) studied HCV and EV71 infection. N-phenylbenzamide and N-phenylacetophenone compounds vs. IMB-1f, IMB-1g, and pirodavir was evaluated on Antiviral activity (IC50) against HCV and EV71. Novel N-phenylbenzamide and N-phenylacetophenone compounds exhibited potent in vitro antiviral activity against HCV and EV71, with compound 23 showing an IC50 of 0.57 μmol/L against HCV.
Synapse has enriched 10 related papers. Consider them for comparative context: